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OBJECTIVE — Weinvestigatedtheeffectsofnormalvariationsinmaternalglycemiaonbirth
size and other birth outcomes.
RESEARCHDESIGNANDMETHODS — Womenintwounselectedbirthcohorts,one
retrospective (n  3,158) and one prospective (n  668), underwent an oral glucose challenge
at28weeksofgestation.Intheretrospectivestudy,glycemiawaslinkedtoroutinebirthrecords.
Intheprospectivestudy,offspringadipositywasassessedbyskinfoldthicknessfrombirthtoage
24 months.
RESULTS — In the retrospective study, within the nondiabetic range (2.1–7.8 mmol/l), each
1 mmol/l rise in the mother’s 60-min glucose level was associated with a (mean  SEM) 2.1 
0.8% (P  0.006) rise in absolute risk of assisted vaginal delivery, a 3.4  0.8% (P  0.0001)
riseinemergencycesareandelivery,a3.10.7%(P0.0001)riseinelectivecesareandelivery,
a n da4 6 8g( P  0.0001) increase in offspring birth weight. In the prospective study, fetal
macrosomia (birth weight 90th centile) was independently related to the mother’s fasting
glucose (odds ratio 2.61 per 1 mmol/l [95% CI 1.15–5.93]) and prepregnancy BMI (1.10 per
1 kg/m
2 [1.04–1.18]). The mother’s higher fasting glycemia (P  0.004), lower insulin
sensitivity (P  0.01), and lower insulin secretion (P  0.02) were independently related to
greater offspring adiposity at birth. During postnatal follow-up, the correlation between the
mother’sglycemiaandoffspringadipositydisappearedby3months,whereasprepregnancyBMI
was associated with offspring adiposity that was only apparent at 12 and 24 months (both P 
0.05).
CONCLUSIONS — Prepregnancy BMI, pregnancy glycemia, insulin sensitivity, and insulin
secretion all contribute to offspring adiposity and macrosomia and may be separate targets for
intervention to optimize birth outcomes and later offspring health.
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T
he international multicenter Hyper-
glycemia and Adverse Pregnancy
Outcomes (HAPO) Study recently
reported that maternal fasting and stimu-
lated glucose levels showed linear effects
on risks for macrosomia, cesarian deliv-
ery, and neonatal hypoglycemia at birth
(1). These ﬁndings question the optimal
indicators used to manage maternal glu-
cose levels during pregnancy.
The elevation in maternal glycemia
during pregnancy is consequent to a rise
in maternal insulin resistance, which in
turn is attributed to hormonal changes,
such as placental growth hormone (2), or
to a maternal inﬂammatory response to
placental cells (3). Higher maternal glu-
cose levels facilitate glucose transport
across the placenta, which in turn pro-
motes fetal insulin secretion and fetal
growth (4). In addition to higher glucose
levels, maternal insulin resistance also el-
evates circulating amino acids and fatty
acids,andthesenutrientscouldalsostim-
ulate fetal insulin secretion and fetal
growth. Therefore, maternal BMI, insulin
sensitivity, and insulin secretion could all
contributetooffspringbirthsizeandbirth
outcomes.
We investigated the relationships be-
tween maternal insulin, glucose, and BMI
during pregnancy and offspring birth size
and adiposity in a prospective study with
follow-up of offspring to age 24 months.
In a separate large retrospective study, we
exploredthenatureoftherelationshipbe-
tween maternal glycemia on birth weight
and mode of delivery.
RESEARCH DESIGN AND
METHODS— The retrospective co-
hort (the Cambridge Wellbeing Study)
comprised mothers identiﬁed from rou-
tine clinical data in an electronic database
of all deliveries at the Rosie Maternity
Hospital, Cambridge, U.K., between
1999 and 2000. The data were merged to
a biochemistry database of maternal ve-
nous blood glucose levels 60 min after a
50-g oral glucose load at 27–29 weeks of
gestation as a routine screening test for
gestational diabetes mellitus. Women
with 60-min glucose levels 7.8 mmol/l
were excluded from this study, as these
women would have been considered at
high risk of gestational diabetes mellitus
(5). We identiﬁed data for 3,158 Cauca-
sian women with normal glucose toler-
ance, who denied smoking or taking any
medication at the time of glucose testing
and who had a subsequent full-term
(37 weeks of gestation) singleton deliv-
ery. Birth weight was measured at deliv-
ery by the midwife.
The prospective cohort (the Cam-
bridge Baby Growth Study) was recruited
from mothers attending ultrasound clin-
ics during early pregnancy at the Rosie
Maternity Hospital between 2001 and
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oral glucose load (oral glucose tolerance
test [OGTT]) was given. Venous blood
glucose and insulin levels were measured
at fasting and at 60 min, and capillary
blood glucose was measured at 30, 90,
and 120 min. Of a total of 708 women
who underwent an OGTT, we excluded
34 (4.8%) who had known diabetes, a
further4womenwhohada120-mincap-
illary glucose level 8.6 mmol/l, and 2
women who had fasting venous glucose
6.1 mmol/l. Complete data on glucose
and insulin levels and offspring birth
weightwereavailablefor668nondiabetic
pregnantwomenwithnormalfastingglu-
cose and glucose tolerance. Birth weight
was measured by the midwife. Offspring
skinfoldthicknesses(biceps,triceps,sub-
scapular, and suprailiac) were measured
at birth (7 days old). Measurements
were performed in duplicate by trained
research nurses using a Harpenden Skin-
fold Caliper (Holtain, Crosswell, Cry-
mych, Pembrokeshire, U.K.).
Ethical approval
Both studies were approved by the local
ethics committee, Addenbrooke’s Hospi-
tal,Cambridge,U.K.Fortheretrospective
Cambridge Wellbeing Study, we only an-
alyzed routinely collected and anony-
mizeddata,andthereforeconsentwasnot
required. For the prospective Cambridge
Baby Growth Study, written informed
consentwasobtainedfromallmothersby
a research nurse.
Assays
In both cohorts, mother’s whole blood glu-
cose levels were taken from routine mea-
surements in the Clinical Biochemistry
Department, Addenbrooke’s Hospital,
U.K., using a standard glucose oxidase–
basedassay.IntheCambridgeBabyGrowth
Study, fasting and stimulated insulin levels
were measured in the Department of Pedi-
atrics. Insulin was measured by enzyme-
linked immunosorbent assay using a
commercial kit (DSL, London, U.K.). Sen-
sitivity was 0.26 mU/l. Intra-assay coefﬁ-
cientsofvariation(CVs)were4.4and5.1%
at10.3and35.8mU/l,andequivalentinter-
assayCVswere8.7and2.9%;thisassayhas
no cross-reactivity with proinsulin at levels
up to 1,000 pmol/l.
Calculations
Insulin sensitivity was estimated using ho-
meostasis model assessment (HOMA) (6).
To estimate insulin secretion independent
of insulin sensitivity, we calculated the dis-
position index as the insulinogenic index
[(insulin60insulin0)/(glucose60glu-
cose0)](7)dividedbytheinsulinresistance
index (8). Offspring adiposity at ages 0, 3,
12, and 24 months was estimated as the
average of the standardized scores for the
four skinfold thickness measurements ad-
justed for age and sex.
Statistics
For the retrospective Cambridge Wellbe-
ingStudy,glucoselevelswerecategorized
into ﬁve groups (4, 4.1–5.0, 5.1–6.0,
6.1–7.0, and 7.1–7.8 mmol/l). Differ-
ences in birth weight and birth outcomes
between these ﬁve groups were analyzed
by ANOVA and 
2 tests for trend. Regres-
sion analyses were also performed using
the continuous variables glucose and
glucose
2 to test for nonlinearity.
For the prospective Cambridge Baby
Growth Study, correlations between con-
tinuous variables were tested by linear
regression,adjustedforpotentialconfound-
ing factors (maternal age, height, smoking
inpregnancy,parity,offspringsex,andges-
tational age). Results of these analyses are
displayed as standardized regression coefﬁ-
cients (). Insulin levels were positively
skewed, and logarithms were calculated to
achieve normal distributions.
RESULTS
Maternal glucose levels and birth
outcomes
In the retrospective Cambridge Wellbe-
ingstudy,associationswereidentiﬁedbe-
tween various birth outcomes and
maternalglucoselevelswithinthenormal
nondiabetic range (glucose level 7.8
mmol/l 60 min after a 50-g glucose load)
(Table 1). Offspring birth weights in-
creased by (mean  SEM) 46  8 g for
each 1 mmol/l rise in maternal 60-min
stimulatedglucoselevel(P0.0001,n
3,158), and a continuous trend was ap-
parent across the range of normal glucose
levels(Table1).Each1mmol/lincreasein
maternalpostchallengeglucoselevelswas
also associated with a rise in the absolute
risk of assisted vaginal deliveries (2.1 
0.8%, P  0.006), emergency cesarean
delivery (3.4  0.8%, P  0.0001), and
elective cesarean delivery (3.1  0.7%,
P  0.0001) (Table 1). No signiﬁcant de-
viation from linearity was observed for
any outcome (data not shown).
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related to offspring birth size
Maternal characteristics of the prospec-
tive Cambridge Baby Growth Study are
displayedinTable2.Amongwomenwith
normal glycemia (fasting glucose 6.1
mmol/land120-minpost–75-gOGTTglu-
coselevel8.6mmol/landreportedlynon-
diabetic), distinct effects of maternal
glucose levels and prepregnancy BMI were
seen on infant birth size (Fig. 1). Mother’s
fasting glucose level was more strongly re-
latedtooffspringskinfolds(0.207,P
0.0001) and weight at birth (0.180,
P  0.0001) than to birth length (
0.097, P  0.02). Conversely, mother’s
prepregnancy BMI was independently re-
lated to offspring birth length (0.104,
P  0.009) and birth weight (0.090,
P0.04)butnottoskinfoldsatbirth(
0.048, P  0.2) (Fig. 1).
The risk of fetal macrosomia (birth
weight 90th centile for gestational age
and sex) was independently related to
both the mother’s fasting glucose (odds
ratio 2.61 per 1 mmol/l [95% CI 1.15–
5.93]) and prepregnancy BMI (1.10 per
1 kg/m
2 [1.04–1.18]).
Maternal insulin and glucose
metabolism and offspring adiposity
Offspring skinfolds at birth were more
strongly related to fasting glucose (
0.222, P  0.0001) than to 30-min glu-
cose (0.086), 60-min glucose (
0.094), 90-min glucose (0.074), or
120-min glucose (0.114, all P 
0.05). Beyond the effect of fasting glu-
cose, stimulated glucose levels did not
further contribute to the variance in off-
springskinfoldsatbirth(datanotshown).
However, independent of the moth-
er’s glucose levels, the mother’s insulin
sensitivity ( 0.129, P  0.01) and
insulin secretion (disposition index, 
0.137, P  0.02) were both inversely
related to offspring skinfolds at birth
(Table 3).
Correlations with adiposity during
infancy
In the prospective Cambridge Baby
Growth Study, prepregnancy BMI corre-
latedpositivelywithoffspringadiposityat
ages 12 and 24 months (both P  0.05).
However, the correlation between the
mother’s glycemia and offspring adipos-
ity,whichhadbeenapparentatbirth,dis-
appearedfromage3monthsonward(Fig.
2). Accordingly, higher maternal fasting
glucose levels were associated with a de-
cline in offspring adiposity between birth
to age 12 months ( 0.218, P 
0.0001).
CONCLUSIONS — In two contem-
porary U.K. cohorts, we observed that in-
creasing maternal glucose levels within
the normal nondiabetic range were con-
sistently related to larger offspring birth
size and increased risk of interventional
deliveries. Maternal glucose levels specif-
ically enhanced offspring adiposity at
birth, and additional inﬂuences of mater-
nal insulin sensitivity and insulin secre-
tion were apparent. Postnatally, the effect
of maternal glycemia on offspring adipos-
ity rapidly disappeared during infancy,
and over the same period a positive effect
of maternal BMI became apparent.
Although gestational diabetes melli-
tus has long been associated with fetal
macrosomia(9),ourdatasupportagrow-
ing number of studies that report a con-
tinuous effect of maternal glucose levels,
Figure 1— Distinct inﬂuences of the mother’s prepregnancy BMI and gestational fasting glucose
level on offspring size at birth (length, weight, and skinfolds). Standardized correlation coefﬁ-
cients (  95% CI) from multivariable models that included both BMI and fasting glucose as
determinantsareshown.*P0.05,alsoadjustedformaternalage,height,smokinginpregnancy,
parity, offspring sex, and gestational age.
Table 2—Characteristics of mothers in the prospective Cambridge Baby Growth Study with
normal glycemia (fasting glucose <6.1 mmol/l and 120 min post–75-g OGTT glucose level
<8.6 mmol/l) and reportedly nondiabetic
Mean Median SD Minimum Maximum
Age (years) 33.3 33.3 4.1 18.1 47.5
Prepregnancy weight (kg) 66.3 63.5 13.1 40.0 143.2
Prepregnancy BMI (kg/m
2) 24.1 23.0 4.4 16.6 48.0
Height (cm) 165.9 165.1 7.1 146.0 190.0
Venous glucose
0 min (mmol/l) 4.3 4.3 0.4 2.7 6.0
60 min (mmol/l) 6.6 6.5 1.5 3.0 13.1
Capillary glucose 120 min
(mmol/l) 6.5 6.5 1.0 2.7 8.6
Insulin
0 min (pmol/l) 51.5 43.6 28.1 5.3 347.0
60 min (pmol/l) 406.4 354.7 239.0 38.9 2,315.8
N  668.
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on offspring birth weight and pregnancy
outcomes (1,10–13). Most recently, the
internationalmulticenterHAPOStudyre-
ported that maternal fasting, 60-min, and
120-minglucoselevelsallshowedsimilar
linear effects on risks for macrosomia, ce-
sarian delivery, neonatal hypoglycemia,
and insulinemia at birth (1). Such ﬁnd-
ings indicate that the current criteria used
to diagnose and manage gestational hy-
perglycemianeedurgentreconsideration.
Ourstudyshowsfortheﬁrsttimethat
in addition to maternal glycemia, differ-
ences in maternal insulin sensitivity, in-
sulin secretion, and BMI also have an
impact on offspring size and adiposity.
These ﬁndings suggest that maternal en-
ergy substrates other than glucose, such
as free fatty acids or amino acids, may
have an important independent inﬂuence
on fetal growth. Although we used the
HOMA model of fasting insulin sensitiv-
ity, smaller studies using the insulinemic-
euglycemic clamp method showed that
maternal insulin sensitivity during preg-
nancy contributes to both offspring body
fat and fat-free mass (14).
The effect of maternal overweight or
obesity on larger offspring size has been
attributed mainly to higher pregnancy
glucose levels. We now show that, inde-
pendent of glycemia, prepregnancy BMI
appears to inﬂuence offspring body
length and weight, rather than adiposity.
In contrast, the major effect of maternal
glycemiaonfetalgrowthwasonadiposity
(15). Fetal length may be determined at a
very early stage during gestation, whereas
increased adiposity may result largely
fromglucosetransporttothefetusduring
thethirdtrimester.Inanimalmodels,ma-
ternal nutrition during the periconcep-
tual period may have important effects on
subsequent fetoplacental growth (16). In
humans, differences in fetal length may
therefore reﬂect early gestational placen-
tation and periconceptual maternal nutri-
tion. Our ﬁndings therefore indicate that
the overweight or obese mother might
somehow enhance early placentation and
early transport of nutrient to the fetus,
possibly by affecting gene methylation
(17).
Offspring of diabetic pregnancies ap-
pear to have increased long-term risks of
obesity (18,19) and impaired glucose tol-
erance (18). It has been suggested that
fetalexposuretoglucoseincreasesrisksof
overweightandtype2diabetesinlaterlife
(13). However, such observational stud-
ies cannot completely separate the spe-
ciﬁc effects of gestational glucose levels
from inherited genetic susceptibility to
overweight and type 2 diabetes. Our data
show that the effect of maternal glycemia
on offspring adiposity is only transitory
and disappears soon after birth. There-
fore, any deleterious long-term effects of
fetal glucose exposure on type 2 diabetes
risk must be more subtle, possibly affect-
ing fetal -cell capacity or adipocyte dis-
tribution and function rather than overall
adiposity. In contrast, we observed that
the“transgenerational”effectsofmaternal
BMI on offspring adiposity emerge early
in infancy and could be explained by
transmission of genetic susceptibility to
obesity (20) or by parental inﬂuences on
infant nutrition.
In summary, the linear nature of the
associations between maternal glycemia
and adverse birth outcomes leads to un-
certainties in the optimal deﬁnition of
gestational hyperglycemia. In addition to
intensive interventions in high-risk indi-
viduals, according to epidemiological
principles, such linear associations indi-
cate that population-based strategies to
reduce glycemia in all pregnant women
would have a greater impact on reducing
adverse pregnancy outcomes in similar
Westernized settings (21). Furthermore,
the aim of such strategies should also be
Figure2—Distinctpostnatalinﬂuencesofthemother’sprepregnancyBMIandgestationalfasting
glucose level on offspring skinfold thicknesses during infancy (birth to 24 months). Standardized
correlation coefﬁcients (  95% CI) from multivariable models that included both BMI and
fasting glucose as determinants are shown. *P  0.05.
Table 3—Final multivariable model of determinants of offspring skinfold thicknesses at birth
in the Cambridge Baby Growth Study
Standardized
coefﬁcient () P value
Signiﬁcant factors
Gestation 0.221 0.001
Female sex 0.111 0.02
Parity 0.127 0.01
Venous glucose 0 min 0.170 0.004
Mother’s insulin sensitivity (HOMA) 0.129 0.01
Mother’s disposition index 0.137 0.02
Nonsigniﬁcant factors
Mother’s age 0.081 0.1
Mother’s height 0.077 0.1
Mother’s BMI 0.049 0.3
Smoking 0.004 0.9
Venous glucose 60 min 0.012 0.9
Birth outcomes in nondiabetic mothers
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and improve insulin sensitivity as these
factors may inﬂuence fetal growth inde-
pendent of maternal glycemia.
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